Core Insights - 60 Degrees Pharmaceuticals, Inc. plans to expand its sales and marketing initiatives for ARAKODA® following positive results from a 6-month commercial pilot that indicated increased market demand among prescribers [1][2][3] Sales and Marketing Initiatives - The company will enhance its integrated digital marketing campaign to improve awareness and engagement with prescribers [2] - The number of inside sales representatives will be increased to strengthen outreach and provider relationships [8] - A partnership with GoodRx will be established to provide broader visibility of ARAKODA offers, facilitating access to savings information for patients and prescribers [8] Clinical Development - The company will add at least two clinical sites for ongoing studies related to babesiosis treatment, responding to FDA feedback regarding its Breakthrough Therapy Designation request [3][4] - The FDA acknowledged that babesiosis meets the criteria for being classified as a serious disease, suggesting the company resubmit its request with data from ongoing clinical trials [3] Product Information - ARAKODA® (tafenoquine) is approved for malaria prophylaxis in the U.S. and has been assessed for safety in five randomized trials lasting up to six months [5][6][20] - Tafenoquine offers potential advantages in less-frequent dosing for malaria prophylaxis due to its long terminal half-life of approximately 16 days [10]

Summary of 60 Degrees Pharmaceuticals FY Conference Call Company Overview - **Company**: 60 Degrees Pharmaceuticals (NasdaqCM:SXTP) - **Focus**: Development and commercialization of small molecule therapeutics for vector-borne diseases, specifically malaria and babesiosis [1][2] Core Product - **Product**: Aracoda, approved for malaria prevention in 2018 - **Sales History**: Entered the US supply chain in September 2019; sales initially impacted by the COVID-19 pandemic but have since increased, with a significant portion attributed to chronic babesiosis [2][3][4] Sales and Market Potential - **Sales Growth**: Sales have stabilized with a gross margin of approximately 50% [4][5] - **Future Sales Potential**: Projected sales could exceed $200 million by 2035, with contributions from malaria prevention (20%), acute babesiosis, and chronic babesiosis [5][6] - **Market Research**: Identified a growing need for malaria prevention due to increasing cases among travelers and the complexity of existing treatment regimens [6][7][8] Commercial Strategy - **Commercial Pilot Program**: Launched to increase brand awareness and sales, including electronic outreach, direct physician contact, and co-pay assistance [10][11] - **Data Expectations**: Anticipated data from the pilot program by the end of 2025, which will inform future scaling decisions [12] Babesiosis Program - **Disease Overview**: Babesiosis is transmitted by ticks and shares similarities with malaria, including symptoms and treatment challenges [12][13] - **Diagnostic Challenges**: The introduction of a new FDA-approved diagnostic test has significantly reduced blood-borne infections, indicating a hidden reservoir of undiagnosed cases [14][15] - **Clinical Trials**: Three trials are underway to explore the efficacy of Tefaniquin for chronic babesiosis, with the goal of enrolling 100 patients [22][24] Research and Development - **Tefaniquin's Efficacy**: Promising results from animal studies and a case series from Yale University suggest Tefaniquin may effectively treat chronic babesiosis [20][21] - **Trial Design**: Trials are designed to confirm chronic babesiosis diagnoses and assess the drug's impact on patient-reported outcomes [25][26] Market Outlook - **Sales Growth**: Increased sales reported in the first half of the year, with expectations for continued growth following the resolution of supply chain issues [26][27] - **Future Catalysts**: Upcoming data releases and regulatory decisions regarding new labeling for babesiosis are expected to drive investor interest [27] Conclusion - **Investor Engagement**: The company is focused on leveraging market research and clinical trial data to enhance its product offerings and expand its market presence in the vector-borne disease space [27][28]